ClinicalTrials.gg
RecruitingNCT07410325LIGHTER-MetSUpdated Apr 8, 2026

Effectiveness and Implementation of a Community-based Health Coach-led Artificial Intelligence (AI)-Powered Digital Self-Regulation Program for Individuals With Metabolic Syndrome (MetS)

An interventional study of LIGHTER-MetS in Metabolic Syndrome (MetS) and Metabolic Syndrome, sponsored by National University Health System, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by National University Health System, Singapore · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Metabolic Syndrome with a site in Singapore — 7 open to participants now, 9 under way, none of them phase 3. Metabolic Syndrome · Singapore.

Started
2026
with 1 other
No phase
7 of 15
3 open now
Registered
14th of 15
by date
Lead sponsor
2 of 15
National University Health System, Singapore

Among the 15 studies in Metabolic Syndrome with a site in Singapore, this one is one of 2 that started in 2026, is one of 7 with no phase, and was the 14th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

7 of the 15 studies in Metabolic Syndrome with a site in Singapore are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Metabolic Syndrome with a site in Singapore, or all of them as a file.
02

Study summary

This study aims to evaluate the effectiveness of the Lifestyle Intervention for Gentle, Healthy Transformation and Enhanced Weight Reduction-metabolic syndrome (LIGHTER-MetS) program on dietary self-regulation and cardiovascular risk among individuals with metabolic syndrome (MetS). The LIGHTER-MetS program, a community-based, grassroots-led initiative, integrates health coaching with the eTRIP© app to promote sustainable lifestyle changes focusing on diet, exercise, and emotion regulation.

03

Conditions studied

  • Metabolic Syndrome (MetS)
  • Metabolic Syndrome

Browse trials for

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. are between 21 to 65 years of age;
  2. have a waist circumference ≥90 cm in men and ≥80 cm in women;
  3. have 2 or more of the following to be classified as having metabolic syndrome:

    • triglyceride level of ≥1.7 mmol/L or on specific treatment for this lipid abnormality;
    • high density lipoprotein (HDL) cholesterol \<1.03 mmol/L in men, and \<1.29 mmol/L in women, or on specific treatment for this lipid abnormality;
    • blood pressure of ≥130/85 mmHg or on treatment of previously diagnosed hypertension;
    • fasting blood glucose level of ≥ 5.6 mmol/L or previously diagnosed type 2 diabetes;
  4. are not receiving other structured lifestyle modification programs;
  5. consent to audio-recording;
  6. English speaking and literate.

Exclusion criteria

Exclusion Criteria:

  1. underwent or are scheduled for metabolic surgery within 1 year;
  2. are pregnant or planning for pregnancy at the time of recruitment;
  3. are unable to speak English;
  4. do not own a smartphone; and
  5. are unable to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
316 participants (estimated)

Study arms

  • Experimental
    LIGHTER-MetS

    The LIGHTER-MetS program includes community-based health coaching by the PI or a trained healthcare professional (e.g. nurse, physiotherapist etc.) at baseline visit and for 3 months following the baseline visit. Throughout the first 3 months, participants will also use the eTRIP© app to log meals, monitor physical activity, and receive personalized feedback. During the 3-month intervention period, there will be one-to-one slots for the health coach to follow up on participants' health plan.

    Behavioral: LIGHTER-MetS

  • No intervention
    Control

    Participants will receive personalised health plans provided as part of usual care when they see a family physician. As part of the HealthierSG initiative, health plans are typically formulated to target early disease prevention and chronic condition management through history taking, physical examination, appropriate diagnostic testing, treatment, referrals and lifestyle modification goals and activity planning.

Interventions

  • BehavioralLIGHTER-MetS

    The LIGHTER-MetS program includes community-based health coaching by the PI or a trained healthcare professional (e.g. nurse, physiotherapist etc.) at baseline visit and for 3 months following the baseline visit. Throughout the first 3 months, participants will also use the eTRIP© app to log meals, monitor physical activity, and receive personalized feedback. During the 3-month intervention period, there will be one-to-one slots for the health coach to follow up on participants' health plan.

06

What researchers measure

Primary outcomes

  1. Self regulation of Eating Behaviour Questionnaire (SREBQ)

    The Self-Regulation of Eating Behaviour Questionnaire (SREBQ) is a validated self-administered instrument used to assess individuals' self-regulation in relation to eating behavior. It evaluates the extent to which individuals monitor, control, and regulate their eating behaviors in everyday contexts. Higher scores indicate greater self-regulation of eating behavior.

    Time frame: At baseline, 3, 6, and 12 months.

  2. Cardiovascular Risk

    Cardiovascular risk will be assessed via the ASCVD-risk calculator and the Singapore-modified Framingham Risk Score 2023 (SG-FRS-2023). Higher scores indicate a greater estimated cardiovascular risk.

    Time frame: At baseline, 3, 6, and 12 months.

Secondary outcomes

  1. Weight

    Time frame: At baseline, 3, 6, and 12 months.

  2. Waist Circumference

    Time frame: At baseline, 3, 6, and 12 months.

  3. Blood Pressure

    Both systolic and diastolic blood pressure will be assessed.

    Time frame: At baseline, 3, 6, and 12 months.

  4. Three Factor Eating Questionnaire (TFEQ)

    The Three-Factor Eating Questionnaire (TFEQ) is a validated self-administered instrument used to assess eating-related behaviors. It measures three domains: cognitive restraint of eating, uncontrolled eating, and emotional eating. Higher scores indicate greater levels of the respective eating behavior.

    Time frame: At baseline, 3, 6 and 12 month.

  5. Consideration of Future Consequences Scale (CFCS-6)

    The Consideration of Future Consequences Scale - 6 item (CFCS-6) is a validated self-administered questionnaire used to assess the extent to which individuals consider the potential future outcomes of their current behaviors. It evaluates the degree to which individuals weigh immediate versus future consequences when making decisions. Higher scores indicate greater consideration of future consequences.

    Time frame: At baseline, 3, 6 and 12 month.

  6. Self-Report Behavioural Automaticity Index (SRBAI)

    The Self-Report Behavioural Automaticity Index (SRBAI) is a validated self-administered questionnaire used to assess the automaticity of behavior. It evaluates the extent to which a behavior is performed automatically, with little conscious thought or deliberation. Higher scores indicate greater behavioral automaticity.

    Time frame: At baseline, 3, 6 and 12 month.

  7. International Physical Activity Questionnaire Short-Form (IPAQ-SF)

    The International Physical Activity Questionnaire - Short Form (IPAQ-SF) is a validated self-administered questionnaire used to assess self-reported physical activity levels. It captures the frequency and duration of walking, moderate-intensity activity, and vigorous-intensity activity performed over the past 7 days.

    Time frame: At baseline, 3, 6 and 12 month.

  8. Generalized Anxiety Disorder 2-item (GAD-2)

    The Generalized Anxiety Disorder - 2 item (GAD-2) is a validated self-administered screening questionnaire used to assess the frequency of core anxiety symptoms over the past two weeks. Higher scores indicate greater anxiety symptom severity.

    Time frame: At baseline, 3, 6 and 12 month.

  9. Patient Health Questionnaire-2 (PHQ-2)

    The Patient Health Questionnaire - 2 item (PHQ-2) is a validated self-administered screening questionnaire used to assess the frequency of depressive symptoms over the past two weeks. Higher scores indicate greater depressive symptom severity.

    Time frame: At baseline, 3, 6 and 12 month.

  10. Perceived Stress Scale (PSS-10)

    The Perceived Stress Scale - 10 item (PSS-10) is a validated self-administered questionnaire used to assess perceived stress levels over the past month. It measures the extent to which individuals perceive situations in their lives as stressful. Higher scores indicate greater perceived stress.

    Time frame: At baseline, 3, 6 and 12 month.

  11. Euro Quality of life 5 Dimensions-5 Levels (EQ-5D-5L)

    The EuroQol 5 Dimensions - 5 Levels (EQ-5D-5L) is a standardized self-administered instrument used to assess health-related quality of life. It measures five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with five response levels.

    Time frame: At baseline, 3, 6 and 12 month.

  12. Big Five Inventory - 44 item (BFI-44)

    The Big Five Inventory - 44 item (BFI-44) is a validated self-administered questionnaire used to assess personality traits across five domains: openness, conscientiousness, extraversion, agreeableness, and neuroticism. Higher scores indicate greater expression of the respective personality traits.

    Time frame: At baseline, 3, 6 and 12 month.

  13. BMI

    Measured using InBody 120.

    Time frame: At baseline, 3, 6 and 12 month.

  14. Percentage Body Fat

    Measured using InBody 120.

    Time frame: At baseline, 3, 6 and 12 month.

  15. Body Fat Mass

    Measured using InBody 120.

    Time frame: At baseline, 3, 6 and 12 month.

  16. Visceral Fat Level

    Measured using InBody 120.

    Time frame: At baseline, 3, 6 and 12 month.

  17. Homeostatic Model Assessment of Insulin Resistance

    Measured using (fasting blood insulin X fasting blood glucose)/22.5.

    Time frame: At baseline, 3 and 12 months.

  18. Fasting Blood Glucose (mmol/L)

    Fasting blood glucose is a biochemical measure of blood glucose concentration after an overnight fast, measured using standard laboratory blood analysis. Higher values indicate poorer glycaemic control.

    Time frame: At baseline, 3, 6 and 12 month.

  19. Glycated haemoglobin (HbA1c) (%)

    Glycated haemoglobin (HbA1c) reflects average blood glucose levels over the preceding two to three months and is measured using standard laboratory blood analysis. Higher values indicate poorer long-term glycaemic control.

    Time frame: At baseline, 3, 6 and 12 month.

  20. Triglycerides (mmol/L)

    Triglycerides are a lipid biomarker measured using standard laboratory blood analysis to assess circulating triglyceride levels. Higher values indicate poorer lipid profiles and increased cardiometabolic risk.

    Time frame: At baseline, 3, 6 and 12 month

  21. High-density lipoprotein cholesterol (HDL-C) (mmol/L)

    High-density lipoprotein cholesterol (HDL-C) is a lipid biomarker measured using standard laboratory blood analysis to assess protective cholesterol levels. Lower values indicate poorer lipid profiles and increased cardiometabolic risk.

    Time frame: At baseline, 3, 6 and 12 month.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Feb 13, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07410325
Lead sponsor
National University Health System, Singapore
Responsible party
Jocelyn Chew (Assistant Professor, National University Health System, Singapore) — Principal investigator
First posted
Feb 13, 2026
Start date
Jan 1, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Apr 8, 2026

Study contacts

Jocelyn Chew
Contact
dbi-lab@nus.edu.sg
+6565168687

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion